These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38125685)
21. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Gisbert JP; Niño P; Cara C; Rodrigo L Aliment Pharmacol Ther; 2008 Jul; 28(2):228-38. PubMed ID: 18485129 [TBL] [Abstract][Full Text] [Related]
22. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Szamosi T; Banai J; Lakatos L; Czegledi Z; David G; Zsigmond F; Pandur T; Erdelyi Z; Gemela O; Papp M; Papp J; Lakatos PL Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):872-9. PubMed ID: 19648821 [TBL] [Abstract][Full Text] [Related]
23. Immunomodulators for all patients with inflammatory bowel disease? Ardizzone S; Cassinotti A; Manes G; Porro GB Therap Adv Gastroenterol; 2010 Jan; 3(1):31-42. PubMed ID: 21180588 [TBL] [Abstract][Full Text] [Related]
24. Medical therapy of inflammatory bowel disease for the 21st century. Robinson M Eur J Surg Suppl; 1998; (582):90-8. PubMed ID: 10029372 [TBL] [Abstract][Full Text] [Related]
26. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Hande S; Wilson-Rich N; Bousvaros A; Zholudev A; Maurer R; Banks P; Makrauer F; Reddy S; Burakoff R; Friedman S Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046 [TBL] [Abstract][Full Text] [Related]
27. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource. Stournaras E; Qian W; Pappas A; Hong YY; Shawky R; ; Raine T; Parkes M; Gut; 2021 Apr; 70(4):677-686. PubMed ID: 33004550 [TBL] [Abstract][Full Text] [Related]
28. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients. Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783 [TBL] [Abstract][Full Text] [Related]
29. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. Nguyen GC; Harris ML; Dassopoulos T Curr Gastroenterol Rep; 2006 Dec; 8(6):499-505. PubMed ID: 17105689 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. Nagy F; Molnar T; Szepes Z; Farkas K; Nyari T; Lonovics J World J Gastroenterol; 2008 Jul; 14(27):4342-6. PubMed ID: 18666323 [TBL] [Abstract][Full Text] [Related]
31. Autoimmune Hemolytic Anemia in Inflammatory Bowel Disease-Report of a Case and Review of the Literature. Toplicanin A; Toncev L; Matovic Zaric V; Sokic Milutinovic A Life (Basel); 2022 Nov; 12(11):. PubMed ID: 36362944 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Hassard PV; Vasiliauskas EA; Kam LY; Targan SR; Abreu MT Inflamm Bowel Dis; 2000 Feb; 6(1):16-20. PubMed ID: 10701145 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Khan KJ; Dubinsky MC; Ford AC; Ullman TA; Talley NJ; Moayyedi P Am J Gastroenterol; 2011 Apr; 106(4):630-42. PubMed ID: 21407186 [TBL] [Abstract][Full Text] [Related]
34. Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from northern India. Ranjan MK; Kante B; Vuyyuru SK; Kumar P; Mundhra SK; Golla R; Sharma R; Sahni P; Das P; Makharia G; Kedia S; Ahuja V J Gastroenterol Hepatol; 2022 Aug; 37(8):1544-1553. PubMed ID: 35501287 [TBL] [Abstract][Full Text] [Related]
35. Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects. Goldstein F J Clin Gastroenterol; 1987 Dec; 9(6):654-8. PubMed ID: 3327885 [TBL] [Abstract][Full Text] [Related]
36. A national survey on the patterns of treatment of inflammatory bowel disease in Canada. Hilsden RJ; Verhoef MJ; Best A; Pocobelli G BMC Gastroenterol; 2003 Jun; 3():10. PubMed ID: 12791168 [TBL] [Abstract][Full Text] [Related]
37. The MYTHS of James SD; Hawkins AT; Um JW; Ballard BR; Smoot DT; M'Koma AE Jpn J Gastroenterol Hepatol; 2020; 3(2):. PubMed ID: 37584007 [TBL] [Abstract][Full Text] [Related]
38. Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease. Vegh Z; Kurti Z; Gonczi L; Golovics PA; Lovasz BD; Szita I; Balogh M; Pandur T; Vavricka SR; Rogler G; Lakatos L; Lakatos PL Scand J Gastroenterol; 2016 Jul; 51(7):848-54. PubMed ID: 26880133 [TBL] [Abstract][Full Text] [Related]
39. Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn's Disease. Kwak MS; Kim KJ; Cheon JH; Kim WS; Lee JM; Hwang SW; Park SH; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK Gastroenterol Res Pract; 2018; 2018():4826973. PubMed ID: 29576767 [TBL] [Abstract][Full Text] [Related]
40. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]